The White House has unveiled significant price reductions for 10 prescription drugs following the first wave of Medicare negotiations mandated by the Inflation Reduction Act (IRA). Most notably, diabetes medications saw the steepest cuts, with Merck's Januvia experiencing a 79% reduction, bringing its monthly price down from $527 to $113. Novo Nordisk's Fiasp also saw a major price drop of 76%, decreasing from $495 to $119. The only cancer treatment on the list, Johnson & Johnson's Imbruvica, had a more modest reduction of 38%, now priced at $9,139 for a monthly regimen. These reductions are expected to save Medicare approximately $6 billion if implemented last year.
While the Biden administration celebrated the price cuts as a historic achievement, pharmaceutical companies expressed concern over the potential consequences. Companies like Johnson & Johnson and Novartis criticized the IRA's pricing strategies, arguing that they could limit patient access to treatments and discourage innovation in drug development. J&J noted that the IRA could lead to higher costs for other patients, and Novartis claimed that its agreement to a "maximum fair price" for its heart failure drug Entresto was made to avoid severe penalties. Bristol Myers Squibb also commented that the negotiated prices do not accurately reflect the clinical value of its drug, Eliquis, which is crucial for preventing strokes.
The negotiated prices will not take effect until 2026, providing some relief for drug manufacturers. However, the ongoing legal battles over the IRA's constitutionality indicate significant pushback from the pharmaceutical industry. Companies have consistently argued that the law restricts their ability to operate freely and undermines their economic viability. As negotiations will expand to more drugs in subsequent years, concerns about access and innovation within the industry remain a focal point of the ongoing debate over drug pricing in the U.S.
Click here to read the original news story.